Kentaro Takeda

Kentaro Takeda

Auto-generated profile, based on publicly available information

Kentaro Takeda

Quantitative Science and Evidence Generation Astellas Pharma Global Development Inc. Northbrook Illinois USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2018 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
PDF file
KTKentaro Takeda
Kentaro Takeda
MTMasataka Taguri
Masataka Taguri
SMSatoshi Morita
Satoshi Morita

12 December 2019 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
PDF file
KTKentaro Takeda
Kentaro Takeda
SMSatoshi Morita
Satoshi Morita
MTMasataka Taguri
Masataka Taguri

28 March 2012 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
SOSeiichiro Ozono
Seiichiro Ozono
TUTakeshi Ueda
Takeshi Ueda
SHSenji Hoshi
Senji Hoshi
AYAkito Yamaguchi
Akito Yamaguchi
HMHideki Maeda
Hideki Maeda
HAHideyuki Akaza
Hideyuki Akaza
To assess the efficacy and safety of degarelix, a new gonadotropin-releasing hormone antagonist, for achieving and maintaining serum testosterone suppression (≤0.5 ng/ml) during the 12-month treatment of Japanese patients with prostate cancer. This Phase II study was conducted as a multicentre, randomized, parallel-group, open-label study. A total of 273 patients with adenocarcinoma of the prostate (any stage) were treated. Degarelix was administered subcutaneously at an initial dose of 240 mg followed by monthly maintenance doses of either 80 or 160 mg for a total of 12 doses. The treatment continued for 12 months. Dose regimens of 240/80 and 240/160 mg maintained castrate levels of testosterone in 94.5 and 95.2% of the patients, respectively. After 3 days, 99.3 and 98.5% of the patients, respectively, reached these levels without a testosterone surge. Prostate-specific antigen levels decreased rapidly following degarelix administration and remained low throughout the study. Best overall response rates according to RECIST were 71.4 (20/28) and 72.7% (16/22), respectively. Eighteen patients (6.6%) withdrew from the study due to adverse events. The most common adverse events were injection site reactions; other adverse events included hot flush, nasopharyngitis, weight increase and pyrexia. Both monthly degarelix dosing regimens were found to be effective in testosterone suppression without a testosterone surge, prostate-specific antigen reductions and anti-tumour effect in Japanese patients with prostate cancer, as was shown in the overseas Phase III study. Degarelix was also well tolerated.

13 May 2022 in Biometrical Journal
Verified
Journal Article
Closed access
KTKentaro Takeda
Kentaro Takeda
SMSatoshi Morita
Satoshi Morita
MTMasataka Taguri
Masataka Taguri

31 July 2018 in Pharmaceutical Statistics
Verified
Journal Article
Closed access
PDF file
KTKentaro Takeda
Kentaro Takeda
KKKanji Komatsu
Kanji Komatsu
SMSatoshi Morita
Satoshi Morita

12 June 2023 in Biometrical Journal
Verified
Journal Article
Closed access
KTKentaro Takeda
Kentaro Takeda
YYYusuke Yamaguchi
Yusuke Yamaguchi
MTMasataka Taguri
Masataka Taguri
SMSatoshi Morita
Satoshi Morita